雷马唑仑联合艾氯胺酮对门诊手术患者麻醉疗效和精神症状的影响:一项随机对照研究。

IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL
Drug Design, Development and Therapy Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S519732
Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang
{"title":"雷马唑仑联合艾氯胺酮对门诊手术患者麻醉疗效和精神症状的影响:一项随机对照研究。","authors":"Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang","doi":"10.2147/DDDT.S519732","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.</p><p><strong>Methods: </strong>A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.</p><p><strong>Results: </strong>Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (<i>p</i><0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (<i>p</i><0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (<i>p</i><0.05). Groups E and ER displayed a shorter extubation time than Group EM (<i>p</i><0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (<i>p</i><0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4527-4535"},"PeriodicalIF":4.7000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132051/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.\",\"authors\":\"Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang\",\"doi\":\"10.2147/DDDT.S519732\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.</p><p><strong>Methods: </strong>A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.</p><p><strong>Results: </strong>Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (<i>p</i><0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (<i>p</i><0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (<i>p</i><0.05). Groups E and ER displayed a shorter extubation time than Group EM (<i>p</i><0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (<i>p</i><0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"4527-4535\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132051/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S519732\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S519732","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:麻醉药物的选择是门诊手术的关键。艾氯胺酮具有麻醉、镇痛和镇静作用,但与剂量依赖性精神症状有关。苯二氮卓类药物可以缓解这些症状,但咪达唑仑等传统药物可能会延长恢复时间。雷马唑仑作为一种新型苯二氮卓类药物,其与艾氯胺酮联用的效果及其对精神症状的影响尚未得到充分的研究。方法:共纳入249例择期腹腔镜手术患者。随机分为艾氯胺酮组(E组)、艾氯胺酮加咪达唑仑组(EM组)、艾氯胺酮加托silate雷马唑仑组(ER组)。主要观察指标是不良反应的发生率。次要结局包括不同时间点的血流动力学:室内休息时(T0)、插管后立即(T1)、拔管后立即(T2)、拔管后30分钟(T3)和离开PACU后立即(T4)。此外,我们还记录了T2-4时的Riker镇静-躁动量表(SAS)评分,以及拔管时间和PACU停留时间。结果:ER组患者术后复视和视力模糊发生率明显低于E组和EM组(ppppppp)。结论:雷马唑仑联合艾氯胺酮可有效减轻术后精神症状,增强血流动力学稳定性,提高恢复质量,是门诊手术可行的麻醉策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.

Background: The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.

Methods: A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.

Results: Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (p<0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (p<0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (p<0.05). Groups E and ER displayed a shorter extubation time than Group EM (p<0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (p<0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (p<0.05).

Conclusion: The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Design, Development and Therapy
Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY
CiteScore
9.00
自引率
0.00%
发文量
382
审稿时长
>12 weeks
期刊介绍: Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信